Deliberately continuing to invest in Belgium is Janssen’s priority. The parent company Johnson & Johnson employs approximately 5,000 people in Belgium, and invests more than a billion euros in research and development each year. 

This means the company also plays an important part in Belgian employment and the economy. Janssen in Belgium is the largest private investor in research and development in the country. In 2013 the company invested some 1,165 billion euros in R&D. These investments are essential for the development of new products and technologies for urgent, as yet unresolved, medical needs. In April 2013 the parent company Johnson & Johnson received a Life Achievement Award from Flanders Investment and Trade as recognition of the role model the company plays in Belgium for domestic and foreign investments.

Investing in the future of R&D-intense sectors such as the pharmaceutical industry is considered important by the company. 

Investing in the future of R&D-intense sectors such as the pharmaceutical industry – one of the mainstays of the Belgian economy – is considered important by the company. Belgium is the third largest exporter of medicines in Europe – after Switzerland and Ireland - with an annual turnover of 34 billion euros in 2013. Moreover, the pharmaceutical sector directly provides more than 32,000 jobs and is good for 40 percent of all Belgian private investment in research and development.

Since 2006, Janssen has regularly come together with GlaxoSmithKline, Pfizer, UCB and with the government to discuss the preservation and further development of an attractive investment climate. The Health, Science and Technology (HST) Group works on ensuring an attractive investment climate.

Besides the focus on Janssen’s permanent embedment in Belgium, the company also maintains durable relationships with the growth countries and countries with the need for innovative and basic medicines. In 2013 Janssen took part in one of the most important economic missions.



Janssen believes that strong corporate results, correct policies and focused activities pave the way towards economic sustainability. 

Janssen must constantly reinvent itself in order to cope with the structural and economic changes that affect its environment. This is why Janssen is committed to build partnerships within an open innovation model, and to the continuous alignment of its cost-competitiveness by only developing medicines with a high therapeutic added value. 

For Janssen this means specifically: being focused and a leader in research & development, and being efficient and progressive in terms of production with the aim of bringing new therapeutic solutions to patients quicker and at less expense, and implementing a growth strategy to ensure our continued investment in all these areas.